Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics of Xiamen, China, and Illumina are collaborating to develop next-generation sequencing cancer diagnostics for the Chinese clinical oncology market, the companies said yesterday.

Under the partnership, AmoyDx will develop and commercialize a series of cancer tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel, which assesses 15 genes that are commonly mutated in solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
09
Sponsored by
Illumina

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.